KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Globus Medical (GMED) Depreciation & Amortization (CF) (2016 - 2025)

Globus Medical's Depreciation & Amortization (CF) history spans 15 years, with the latest figure at $69.0 million for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 2.1% year-over-year to $69.0 million; the TTM value through Dec 2025 reached $276.8 million, up 9.26%, while the annual FY2025 figure was $276.8 million, 9.26% up from the prior year.
  • Depreciation & Amortization (CF) reached $69.0 million in Q4 2025 per GMED's latest filing, down from $71.1 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $72.0 million in Q4 2023 to a low of $16.8 million in Q3 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $40.7 million, with a median of $28.3 million recorded in 2021.
  • Peak YoY movement for Depreciation & Amortization (CF): dropped 11.52% in 2022, then surged 325.52% in 2023.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $16.8 million in 2021, then grew by 0.48% to $16.9 million in 2022, then skyrocketed by 325.52% to $72.0 million in 2023, then fell by 6.06% to $67.6 million in 2024, then increased by 2.1% to $69.0 million in 2025.
  • Per Business Quant, the three most recent readings for GMED's Depreciation & Amortization (CF) are $69.0 million (Q4 2025), $71.1 million (Q3 2025), and $70.6 million (Q2 2025).